medigraphic.com
ISSN 1995-9427 (Impreso)

2016, Número 1

<< Anterior

Invest Medicoquir 2016; 8 (1)


Un candidato vacunal para tumores sólidos con factor de crecimiento del endotelio vascular como diana

Hind Selman-Housein BK, Hernández BF, Morera DY, Martín BY, Ayala ÁM, Gavilondo CJV

Idioma: Español
Referencias bibliográficas: 24
Paginas: 148-155
Archivo PDF: 145.37 Kb.


RESUMEN

Se realiza un reporte breve que brinda información sobre la racionalidad de las inmunoterapias activas y pasivas en cáncer. Se presenta un candidato vacunal para tumores sólidos con el factor de crecimiento del endotelio vascular como diana; sus principales resultados en preclínica que avalaron su paso a la investigación en seres humanos. Se discuten los beneficios de las inmunoterapias activas sobre las pasivas, exponiendo las diferencias entre ellas, analizando los reportes de seguridad del ensayo clínico fase I del candidato vacunal presentado, contra el antiangiogénico por excelencia aprobado para su uso en seres humanos (bevacizumab).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization (WHO). World Cancer Report; 2014.

  2. Ministerio de Salud Pública. Anuario Estadístico de Cuba; 2014.

  3. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. J Biotechnol. 2006;1(2):138-47.

  4. Senger DR. Vascular endothelial growth factor: Much more than an angiogenesis factor. Molecular Biology of the Cell. 2010;21:377-9.

  5. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol. 2002;29:10-4.

  6. Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbial Immunol. 1999;237:133-58.

  7. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005;(94):209-31.

  8. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-4.

  9. Ohm JE. VEGF inhibits T-cell development and may contribute to tumor induced immune suppression. Blood. 2003;101:48-78.

  10. Wei YQ, Huang MJ, Yang I, Zhao x, Tian L, Lu Y, et al. Immunogene therapy of tumors with vaccine based gous vascular endothelial growth factor as model antigen. USA. 2001;98:11545-11550.

  11. Jiang C, Xiong W, Lu BY, Gonda MA, Chang JY. Synthesis and immune response of non-native isomers of vascular endothelial growth factor. Biochemestry. 2010;49:6550-6556.

  12. Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol. 2010;119:564-70.

  13. Kyutoku M, Nakagami H, Koriyama H, Tomioka H, Nakagami F, Shimamura M, et al. Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep. 2013;3:3380.

  14. Hurwitz H. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.

  15. Sandler A. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med. 2006;355:2542-50.

  16. Miller K. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.

  17. Vredenburgh JJ. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-9.

  18. Morera Y. Antitumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogen. 2008;11:381-93.

  19. Estevez F. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999;18:190-7.

  20. Mesa C. Very small size proteoliposomes derived from neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine. 2004;22:3045-52.

  21. Mesa C. Very small size proteoliposomes derived from neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine. 2006;24:2692-9.

  22. Fernández A. Nanoparticulated adjuvant suppressor cell function by a inhibition of tumor induced myeloid derived. J Immunol. 2010;40:22-35.

  23. Bequet-Romero M. Prophylactic DNA vaccination with the human vascular endothelial growth factor induces anti-tumor response in C57Bl/6 mice. Angiogen. 2007;10:23-34.

  24. Morera Y. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non human primates. Vaccine. 2010;28:3453-61.




2020     |     www.medigraphic.com